复发或难治性侵袭性B细胞淋巴瘤的新疗法可提高生存率：来自GELTAMO组RELINF注册研究的分析 - Suppr

New therapies for relapsed or refractory aggressive B-cell lymphoma increase survival: Analysis from the RELINF registry of the GELTAMO group.

作者信息

Bastos-Oreiro Mariana, Abrisqueta Pau, Gutierrez Antonio, Jiménez Ubieto Ana, Poza Maria, Fernanez-Caldas Paula, LLacer María José, Gonzalez de Villambrosia Sonia, Córdoba Raúl, López Alberto, Ceballos Elena, Navarro Belen, Muntañola Ana, Donato Eva, Diez-Baeza Eva, Escoda Lourdes, Luzardo Hugo, Peñarrubia María José, García Belmonte Daniel, Pardal Emilia, Lozada Claudia, Martín García-Sancho Alejandro

机构信息

Hospital Universitario Gregorio Marañon. Instituto de investigación Sanitaria Gregorio Marañon (IiSGM) Madrid Spain.

Hospital Vall d Ebron Barcelona Spain.

出版信息

Hemasphere. 2024 Apr 22;8(4):e70. doi: 10.1002/hem3.70. eCollection 2024 Apr.

DOI:10.1002/hem3.70

PMID:38650598

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11033920/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/00f9/11033920/09cf02e5fb9d/HEM3-8-e70-g001.jpg

相似文献

New therapies for relapsed or refractory aggressive B-cell lymphoma increase survival: Analysis from the RELINF registry of the GELTAMO group.

Hemasphere. 2024 Apr 22;8(4):e70. doi: 10.1002/hem3.70. eCollection 2024 Apr.

RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group.

Ann Hematol. 2020 Apr;99(4):799-808. doi: 10.1007/s00277-020-03918-6. Epub 2020 Feb 20.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Drugs. 2003;63(8):803-43. doi: 10.2165/00003495-200363080-00005.

Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study.

Transplant Cell Ther. 2023 Dec;29(12):747.e1-747.e10. doi: 10.1016/j.jtct.2023.08.026. Epub 2023 Sep 1.

Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial.

Biol Blood Marrow Transplant. 2017 Jan;23(1):53-59. doi: 10.1016/j.bbmt.2016.10.003. Epub 2016 Oct 19.

[Prognostic value of international prognostic index, revised international prognostic index, enhanced international prognostic index and Grupo Español de Linfomas/trasplante autólogo de médula ósea-international prognostic index for diffuse large B-cell lymphoma].

Zhonghua Zhong Liu Za Zhi. 2020 Nov 23;42(11):949-954. doi: 10.3760/cma.j.cn112152-20200329-00271.

Differential prognostic impact of GELTAMO-IPI in cell of origin subtypes of Diffuse Large B Cell Lymphoma as defined by the Hans algorithm.

Br J Haematol. 2018 Aug;182(4):534-541. doi: 10.1111/bjh.15446. Epub 2018 Jul 5.

Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry.

Acta Haematol. 2020;143(1):40-50. doi: 10.1159/000500666. Epub 2019 Jul 17.

[Evaluation of GELTAMO-IPI for Patients with Diffuse Large B-cell Lymphoma].

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021 Feb;29(1):98-103. doi: 10.19746/j.cnki.issn.1009-2137.2021.01.016.

Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups.

Front Immunol. 2022 Jul 12;13:855730. doi: 10.3389/fimmu.2022.855730. eCollection 2022.

引用本文的文献

Chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study.

Hemasphere. 2025 Feb 4;9(2):e70077. doi: 10.1002/hem3.70077. eCollection 2025 Feb.

本文引用的文献

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

N Engl J Med. 2022 Dec 15;387(24):2220-2231. doi: 10.1056/NEJMoa2206913. Epub 2022 Dec 11.

A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma.

Nat Med. 2022 Oct;28(10):2145-2154. doi: 10.1038/s41591-022-01969-y. Epub 2022 Sep 22.

Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups.

Front Immunol. 2022 Jul 12;13:855730. doi: 10.3389/fimmu.2022.855730. eCollection 2022.

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.

Leukemia. 2022 Jul;36(7):1720-1748. doi: 10.1038/s41375-022-01620-2. Epub 2022 Jun 22.

CAR T-Cell Therapy for Large B-Cell Lymphoma - Who, When, and How?

N Engl J Med. 2022 Feb 17;386(7):692-696. doi: 10.1056/NEJMe2118899. Epub 2021 Dec 14.

Diffuse large B cell lymphoma (DLBCL) in patients older than 65 years: analysis of 3 year Real World data of practice patterns and outcomes in England.

Br J Cancer. 2022 Jan;126(1):134-143. doi: 10.1038/s41416-021-01525-4. Epub 2021 Oct 5.

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.

Lancet. 2021 Sep 25;398(10306):1157-1169. doi: 10.1016/S0140-6736(21)00889-8. Epub 2021 Sep 8.

Diffuse Large B-Cell Lymphoma.

N Engl J Med. 2021 Mar 4;384(9):842-858. doi: 10.1056/NEJMra2027612.

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.

Lancet. 2020 Sep 19;396(10254):839-852. doi: 10.1016/S0140-6736(20)31366-0. Epub 2020 Sep 1.

Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity.

J Clin Oncol. 2020 Sep 20;38(27):3095-3106. doi: 10.1200/JCO.19.02103. Epub 2020 Jul 15.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

New therapies for relapsed or refractory aggressive B-cell lymphoma increase survival: Analysis from the RELINF registry of the GELTAMO group.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献